JPRN-jRCT2080221454未知1 期
A Phase 1 Dose-Escalation Study of LY2603618 in Combination with Gemcitabine in Japanese Patients with Solid Tumors
试验速览
- 阶段
- 1 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Have histological or cytological or imaging evidence of a diagnosis of cancer that is advanced and/or metastatic disease
- •- Patient who is planned to have gemcitabine therapy at the proposed doses because he/she was not able to benefit from standard therapy and/or therapies known to provide clinical benefit or there is no standard therapy for the advanced and/or metastatic disease globally
- •- Have adequate organ function
- •- Have a performance status of 0-2 on the ECOG scale
- •- Have discontinued all previous therapies for cancer, including chemotherapy,cancer-related hormonal therapy, or other investigational therapy for at least 30 days (42 days for mitomycin C or nitrosoureas) prior to study enrollment and recovered from the acute effects of therapy
- •- Prior radiation therapy for treatment of cancer is allowed to less than 25% of the bone marrow, and patients must have recovered from the acute toxic effects of their treatment prior to study enrollment. Prior radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed at least 30 days prior to study enrollment
- •- Have an estimated life expectancy of at least 12 weeks
排除标准
- 未提供
研究者
相似试验
未知
1 期
Phase 1 Dose-Escalation Study of LY2157299 Monotherapy in Patients With Solid TumorsSolid TumorJPRN-jRCT2080221965Eli Lilly Japan K.K.
进行中（未招募）
1 期
Phase I study of LDK378 in pediatric malignancies with a genetic alteration in ALKmalignancies characterized by genetic abnormalities in anaplastic lymphoma kinase (ALK)EUCTR2012-002074-31-GBovartis Pharma Services AG83
进行中（未招募）
1 期
The first phase of a study in which young patients that have diseases where an enzyme called anaplastic lymphoma kinase (ALK) is changed from it's original form are treated by increasing doses of the drug LDK378 and where all study participants are aware of what treatment the patients are receiving.EUCTR2012-002074-31-NLovartis Pharma Services AG83
进行中（未招募）
1 期
A Phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK) - Phase I study of LDK378 in pediatric malignancies with a genetic alteration in ALKmalignancies characterized by genetic abnormalities in anaplastic lymphoma kinase (ALK)EUCTR2012-002074-31-FRovartis Pharma Services AG80
已完成
2 期
A Phase I, open-label, dose escalation study of LDK378 in pediatric patients with malignancies that have a genetic alteration in anaplastic lymphoma kinase (ALK)Alle maliginiteiten met een ALK mutatie.malignancies with ALK-aberrationspediatric cancer10027655NL-OMON46950ovartis6